300841.SZ Stock Analysis
30
Neutral
Based on Eyestock quantitative analysis, 300841.SZ`s fundamental data and valuation indicate an investment grade of Neutral at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly undervalued
Chengdu Kanghua Biological Products Co., Ltd. engages in the production and sale of preventive biological products. The company is headquartered in Chengdu, Sichuan and currently employs 588 full-time employees. The company went IPO on 2020-06-16. The firm's main products are Rabies Vaccine (human diploid cell) for Human Use, Freeze-dried and Group ACYW135 Meningococcal Polysaccharide Vaccine. The firm distributes its products in domestic market and to overseas markets.